MetaCap

Kazia Therapeutics (KZIA) vs Tenax Therapeutics (TENX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Kazia Therapeutics (KZIA) has outperformed Tenax Therapeutics (TENX) over the past year, losing 41.1% versus a loss of 84.7%. Over five years, KZIA leads with a -99.0% price change compared with -99.9% for TENX. Tenax Therapeutics is the larger company by market cap ($56.9 million vs $56.2 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

KZIA-41.08%TENX-84.66%
+135%+20%-95%
Nov 21, 20251 yearNov 20, 2026
KZIA-99.13%TENX-99.94%
+5%-50%-105%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

KZIA versus TENX key metrics
MetricKZIATENX
Share price$4.92$1.25
Market cap$56.22M$56.92M
1-day change-8.38%-10.07%
YTD return-28.59%-89.75%
1-year return-41.08%-84.66%
5-year return-99.01%-99.94%
EPS (TTM)$-6.85$-1.39
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$0
Net income (latest FY)—$-52.60M
52-week high$17.40$19.40
52-week low$4.50$1.24
Distance from 52-week high-71.72%-93.56%
Analyst consensusnonenone
Avg. price target upside+476.02%+904.80%
Average volume307.30K3.15M
Shares outstanding11.43M45.54M
Employees614
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • KZIA has outperformed TENX by 43.6 percentage points over the past year.

About Kazia Therapeutics

KZIA stock →

Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel. The company's lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase II/III clinical trial for the treatment of glioblastoma; in Phase II trial to treat isocitrate dehydrogenase-mutant glioma, primary central nervous system (CNS) lymphoma, diffuse intrinsic pontine glioma, and brain metastases; and in pre-clinical studies to treat triple-negative breast cancer, as well as for the treatment of atypical rhabdoid/teratoid tumors.

Health Care · Biotechnology: Pharmaceutical Preparations · 6 employees

About Tenax Therapeutics

TENX stock →

Tenax Therapeutics, Inc., a development-stage pharmaceutical company, develops novel cardiopulmonary therapies in the United States. It develops TNX-101, TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension in heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.

Health Care · Biotechnology: Pharmaceutical Preparations · 14 employees

KZIA vs TENX FAQ

Which is bigger, Kazia Therapeutics or Tenax Therapeutics?

Tenax Therapeutics (TENX) is larger, with a market capitalization of $56.92M compared with $56.22M for Kazia Therapeutics (KZIA).

Which stock has performed better over the past year, KZIA or TENX?

KZIA returned -41.08% over the past 12 months, compared with -84.66% for TENX (price return, excluding dividends). Past performance does not predict future results.

Are Kazia Therapeutics and Tenax Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons